Humira and the Looming Biosimilar Boom
A wave of FDA-approved biosimilars for Humira and other costly biologics will enter the U.S. market in 2023. What does it mean for patients, payers and plan designs?
- Select Category
- Engagement
- Events
- Healthcare Costs
- Media
- Member Stories
- Our Team
- Privacy and Security
- Product
- Success Stories
- Transparency
- Uncategorized
- Select Category
- Engagement
- Events
- Healthcare Costs
- Media
- Member Stories
- Our Team
- Privacy and Security
- Product
- Success Stories
- Transparency
- Uncategorized
No, We’re Not Your Doctor—Just Transparency You Can Trust
Members shouldn’t confuse our clinical suggestions for intervention. Medication decisions are between patient and doctor. RxSS informs those discussions, and makes it easy to make a change.
Considering a PBM’s Savings Tool? 10 Questions to Ask Right Now
Free PBM tools can help members get more from their pharmacy benefits, maybe even save on certain prescriptions. What more can you ask for? Quite a bit, actually.
A Glimpse of the Holy Grail for Healthcare Cost Transparency
Seemingly since the beginning of time, consumers have rarely known what a doctor visit, medical procedure or medication will cost until it’s time to pay. Fortunately, things are starting to change.
Specialty Copay Programs – Accumulate, Maximize or Avoid?
Utilization of specialty medications continues to rise, and so do costs for patients and plan sponsors. Thanks to these rising costs, we see more plans choosing to implement copay adjustment programs, but it’s crucial to understand how they fit into your benefit and where they improve or hinder your plan.
Why Are the Most Important Rx Decision-makers Still in the Dark?
The only people who can write prescriptions typically have no idea what patients will pay at the pharmacy. It’s time to solve this problem.
Let’s Talk About Mental Health
Every May we raise awareness about mental health as we continue to help our members stay adherent by showing them affordable options for the medications they need.
Success With Point Benefit Solutions Hinges on the Pharmacy Factor
Many point benefits solutions have produced positive results for employers and health plans. However, their full potential depends on medication access and affordability.
Generic Dexilant® Joins the PPI Party, But Plenty of Alternatives Already Have
A widely prescribed acid reflux medication now has an authorized generic available. Good news, but five low-cost proton-pump inhibitor (PPIs) generics often work just as well.
Whatever the Numbers Say, Guess Who Keeps Paying More for Rx?
January produced another price hike party from drug makers. But some data indicate prescription prices are actually falling. For consumers? Same as it ever was, or worse.
Stay COnnected
Share your email and once a month we’llsend you industry news and insights.
